We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.025 | 1.25% | 2.025 | 1.95 | 2.10 | 2.025 | 1.975 | 2.00 | 632,383 | 16:11:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.39 | 15.66M |
TIDMSTX
RNS Number : 1285D
Shield Therapeutics PLC
29 January 2018
Shield Therapeutics plc
("Shield" or the "Group")
Notice of Results
London, UK, 29 January 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders, announces it will report its results for the year ended 31 December 2017 on Wednesday, 28 February 2018.
Carl Sterritt, Chief Executive Officer and Karl Keegan, Chief Financial Officer, will host a presentation and conference call for analysts at 9.30 a.m. GMT on the morning of the results in the Guildhall Room at 85 Gresham Street, London EC2V 7NQ.
-Ends-
For further information please contact:
+44 (0) 207 186 Shield Therapeutics plc 8500 Karl Keegan, Chief Financial Officer Fleur Wood, Director, Investor Relations Nominated Adviser and Joint +44 (0)20 3100 Broker 2222 Liberum Capital Limited Christopher Britton/Steve Pearce + 44 (0)20 7418 Joint Broker 8900 Peel Hunt LLP James Steel/Christopher Golden +44 (0)203 709 Financial PR Adviser 5700 Consilium Strategic Communications shieldtherapeutics@consilium-comms.com Mary-Jane Elliott/Matthew Neal US Investor Relations +1 (212) 867 1762 Lazar Partners Fern Lazar/David Carey
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORDBGDBGGDBGII
(END) Dow Jones Newswires
January 29, 2018 02:00 ET (07:00 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions